860502P

C2 Ceramide (d18:1/2:0)

Avanti Research^™ - A Croda Brand 860502P, powder

• Sinónimos: N-acetoyl-D-erythro-sphingosine
• Fórmula empírica (notación de Hill): C₂₀H₃₉NO₃
• Número de CAS: 195194-58-2
• Peso molecular: 341.53
• UNSPSC Code: 12352211
• NACRES: NA.25

Propiedades

• form: powder
• packaging: pkg of 1 × 5 mg (860502P-5mg)
• manufacturer/tradename: Avanti Research^™ - A Croda Brand 860502P
• lipid type: sphingolipids
• shipped in: dry ice
• storage temp.: −20°C
• SMILES string: OC[C@]([H])(NC(C)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)/b16-15+/t19-,20+/m0/s1
• InChI key: BLTCBVOJNNKFKC-QUDYQQOWSA-N

Descripción

General description

C2 Ceramide (d18:1/2:0) is a short-chain ceramide. In general ceramides are synthesized by de novo pathway from palmitic acid via series of intermediates to ceramidein the presence of dihydroceramide Δ4-desaturase.

Application

C2 Ceramide (d18:1/2:0) has been used to treat protoplasts for reactive oxygen species generation and as an substrate for sphingomyelin synthase 2 enzyme. It is suitable for use as an exogenous supplement in hippocampal cell cultures for the production of 2-hydroxyeicosatetraenoic acid (12-(S)-HETE).

Biochem/physiol Actions

C2 ceramide inhibits the progression of human bronchocarcinoma by modulating the matrix metallopeptidases-2 levels. It also inhibits glioma invasion and induces apoptosis in HT-29 and HCT-116 human colon cancer cells. Treatment of myotubes with C2-ceramide leads to decrease in glucose uptake and glycogen synthesis. C2 along with C6 ceramides induces insulin resistance in myoblastic C2C12 cell line and L6 myotubes.

Packaging

5 mL Amber Glass Screw Cap Vial (860502P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3